VALNEVA SE SP.ADS/2 (F:AYJ0) — Market Cap & Net Worth
Market Cap & Net Worth: VALNEVA SE SP.ADS/2 (AYJ0)
VALNEVA SE SP.ADS/2 (F:AYJ0) has a market capitalization of $438.08 Million (€374.72 Million) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #12787 globally and #1367 in its home market, demonstrating a 2.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VALNEVA SE SP.ADS/2's stock price €4.32 by its total outstanding shares 94823458 (94.82 Million). See VALNEVA SE SP.ADS/2 (AYJ0) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
VALNEVA SE SP.ADS/2 Market Cap History: 2021 to 2026
VALNEVA SE SP.ADS/2's market capitalization history from 2021 to 2026. Data shows change from $5.48 Billion to $478.91 Million (-28.15% CAGR).
VALNEVA SE SP.ADS/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VALNEVA SE SP.ADS/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.63x
VALNEVA SE SP.ADS/2's market cap is 4.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.48 Billion | $348.08 Million | -$73.42 Million | 15.73x | N/A |
| 2022 | $1.37 Billion | $361.30 Million | -$143.28 Million | 3.79x | N/A |
| 2023 | $1.01 Billion | $153.71 Million | -$101.43 Million | 6.56x | N/A |
| 2024 | $487.78 Million | $169.58 Million | -$12.25 Million | 2.88x | N/A |
| 2025 | $809.27 Million | $174.66 Million | -$115.19 Million | 4.63x | N/A |
Competitor Companies of AYJ0 by Market Capitalization
Companies near VALNEVA SE SP.ADS/2 in the global market cap rankings as of August 4, 2026.
Key companies related to VALNEVA SE SP.ADS/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
VALNEVA SE SP.ADS/2 Historical Marketcap From 2021 to 2026
Between 2021 and today, VALNEVA SE SP.ADS/2's market cap moved from $5.48 Billion to $ 478.91 Million, with a yearly change of -28.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €478.91 Million | -40.82% |
| 2025 | €809.27 Million | +65.91% |
| 2024 | €487.78 Million | -51.65% |
| 2023 | €1.01 Billion | -26.32% |
| 2022 | €1.37 Billion | -75.00% |
| 2021 | €5.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of VALNEVA SE SP.ADS/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $438.08 Million USD |
| MoneyControl | $438.08 Million USD |
| MarketWatch | $438.08 Million USD |
| marketcap.company | $438.08 Million USD |
| Reuters | $438.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more